Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • Investors
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • Investors
    ►
      ◄ Back
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Dec 21, 2020

TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference

Dec 13, 2020

TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

Dec 11, 2020

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors

Nov 12, 2020

TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020

TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity

Sep 29, 2020

TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Sep 08, 2020

TCR² Therapeutics to Participate in Two Upcoming Conferences in September

Aug 12, 2020

TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 06, 2020

TCR² Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Jul 28, 2020

TCR² Therapeutics Announces Pricing of Public Offering of Common Stock

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
  • Our Science
  • Our Pipeline
  • Patients
  • Investors
  • Get in Touch
  • Join Us
  • Privacy Policy
  • Disclaimer
  • Terms of Use
  • Supply Terms

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics